ATE485059T1 - Tumortherapie mit vektoren auf sindbis virus- basis - Google Patents

Tumortherapie mit vektoren auf sindbis virus- basis

Info

Publication number
ATE485059T1
ATE485059T1 AT02728587T AT02728587T ATE485059T1 AT E485059 T1 ATE485059 T1 AT E485059T1 AT 02728587 T AT02728587 T AT 02728587T AT 02728587 T AT02728587 T AT 02728587T AT E485059 T1 ATE485059 T1 AT E485059T1
Authority
AT
Austria
Prior art keywords
vectors
sindbis virus
based vectors
tumor therapy
alphavirus
Prior art date
Application number
AT02728587T
Other languages
English (en)
Inventor
Daniel Meruelo
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Application granted granted Critical
Publication of ATE485059T1 publication Critical patent/ATE485059T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02728587T 2001-03-27 2002-03-27 Tumortherapie mit vektoren auf sindbis virus- basis ATE485059T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27905101P 2001-03-27 2001-03-27
US31137301P 2001-08-10 2001-08-10
PCT/US2002/009432 WO2002076468A1 (en) 2001-03-27 2002-03-27 Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors

Publications (1)

Publication Number Publication Date
ATE485059T1 true ATE485059T1 (de) 2010-11-15

Family

ID=26959427

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02728587T ATE485059T1 (de) 2001-03-27 2002-03-27 Tumortherapie mit vektoren auf sindbis virus- basis

Country Status (9)

Country Link
US (5) US7306792B2 (de)
EP (1) EP1383513B1 (de)
JP (1) JP5089847B2 (de)
CN (1) CN1520303B (de)
AT (1) ATE485059T1 (de)
AU (1) AU2002258631B2 (de)
CA (1) CA2440890C (de)
DE (1) DE60238044D1 (de)
WO (1) WO2002076468A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2440890C (en) * 2001-03-27 2011-07-19 New York University Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
CA2575591A1 (en) * 2003-08-08 2005-02-17 Yuji Shino A pharmaceutical composition for treatment of cancers
US7910093B2 (en) * 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
WO2005118802A2 (en) 2004-06-03 2005-12-15 The Regents Of The University Of California Targeting pseudotyped retroviral vectors
US7303898B2 (en) 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
WO2009105673A2 (en) * 2008-02-21 2009-08-27 New York University Tumor therapy with replication competent sindbis viral vectors
WO2010005704A2 (en) * 2008-06-13 2010-01-14 New York University Novel helper plasmid, defective sindbis viral vectors and methods of use thereof
US20110010782A1 (en) * 2009-07-09 2011-01-13 Microsoft Corporation Adapting parasites to combat disease
JP5817053B2 (ja) * 2010-04-02 2015-11-18 国立大学法人 千葉大学 腫瘍特異性を有するリポソーム
AU2014318015B2 (en) * 2013-09-06 2020-02-27 New York University Method for inducing antitumor immunity using sindbis viral vectors and tumor associated antigens
WO2017152042A2 (en) * 2016-03-04 2017-09-08 New York University Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
WO2018161092A1 (en) 2017-03-03 2018-09-07 New York University Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins
WO2019136316A1 (en) * 2018-01-04 2019-07-11 Washington University Compositions and methods for inhibition of alphavirus infection
EP3762023A4 (de) 2018-03-05 2021-12-29 New York University Induktion und verbesserung der antitumor-immunität durch sindbis-virusvektoren mit expression von immun-kontrollpunkt-proteinen
EP3997125A1 (de) 2019-07-08 2022-05-18 New York University Tumorimmuntherapie unter verwendung von viralen sindbis-vektoren und agonistischen monoklonalen antikörpern
JP2023548746A (ja) 2020-10-13 2023-11-21 クリヤ セラピューティクス インコーポレイテッド サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
CN116716350A (zh) * 2023-01-18 2023-09-08 中国科学院深圳先进技术研究院 表达il-12的sinv载体及其在制备抗肿瘤药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US6770283B1 (en) 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
FR2746110B1 (fr) * 1996-03-14 1998-04-17 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6458560B1 (en) 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
JP2001515493A (ja) * 1997-03-14 2001-09-18 セレクティブ ジェネティックス，インコーポレイテッド 改変された親和性を有するアデノウイルスベクター
EP1905304A3 (de) * 1997-10-09 2008-08-13 Wellstat Biologics Corporation Behandlung von Neoplasmen mit Viren
US7470426B1 (en) * 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
WO1999044423A1 (en) 1998-03-03 1999-09-10 The Uab Research Foundation Amplification of gene transfer and gene therapy by controlled replication
CN1230595A (zh) * 1998-04-02 1999-10-06 武汉大学 缺失调亡抑制基因病毒的构建及在肿瘤基因治疗中的应用
CN1258742A (zh) * 1998-12-25 2000-07-05 华西医科大学 治疗肿瘤抑制基因p53缺陷肿瘤的重组毒素腺病毒突变体
WO2000039318A1 (en) 1998-12-31 2000-07-06 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
US6329201B1 (en) 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
CN1477964A (zh) * 1999-04-15 2004-02-25 应用病毒治疗肿瘤
US6730297B1 (en) 1999-05-28 2004-05-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
EP1276888A2 (de) * 2000-04-26 2003-01-22 Crucell Holland B.V. Adenovirale vektoren ohne knob-domäne im fiber protein, und verwendungen davon
WO2002074920A2 (en) 2001-03-16 2002-09-26 Johns Hopkins University A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
CA2440890C (en) * 2001-03-27 2011-07-19 New York University Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
CA2575591A1 (en) * 2003-08-08 2005-02-17 Yuji Shino A pharmaceutical composition for treatment of cancers

Also Published As

Publication number Publication date
US20090081131A1 (en) 2009-03-26
US7306792B2 (en) 2007-12-11
WO2002076468A1 (en) 2002-10-03
US20040102410A1 (en) 2004-05-27
CN1520303B (zh) 2013-04-24
EP1383513B1 (de) 2010-10-20
JP5089847B2 (ja) 2012-12-05
EP1383513A1 (de) 2004-01-28
US20090081283A1 (en) 2009-03-26
AU2002258631B2 (en) 2007-05-17
EP1383513A4 (de) 2006-03-29
DE60238044D1 (de) 2010-12-02
CA2440890C (en) 2011-07-19
CN1520303A (zh) 2004-08-11
US20090041726A1 (en) 2009-02-12
US20080125391A1 (en) 2008-05-29
CA2440890A1 (en) 2002-10-03
US7807147B2 (en) 2010-10-05
JP2004532832A (ja) 2004-10-28

Similar Documents

Publication Publication Date Title
DE60238044D1 (de) Tumortherapie mit vektoren auf sindbis virus-basis
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
SA520420526B1 (ar) Caix، بروتينات ربط متعددة النوعية تستهدف أوano1،أو ميسوثيلين، أوtrop2،أوcea، أو كلاودين-18.2
EP4527466A3 (de) Chimäre anti-dll3-antigenrezeptoren und verwendungen davon
EP1844077A4 (de) Dr5-antikörper und deren verwendung
MXPA03000527A (es) Composiciones y metodos para la terapia y diagnostico de cancer ovarico.
EP4461318A3 (de) Neuartige antikörper-wirkstoff-konjugate gegen prostataspezifisches membranantigen (psma)
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
DE602006011030D1 (de) Tumorassoziierte peptide, die promiskuitiv an humane leukozytenantigen- (hla-) moleküle der klasse ii binden
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
DE602006019446D1 (de) An humane leukozytenantigen-(hla-)klasse-i- oder ii-moleküle bindende tumorassoziierte peptide und damit im zusammenhang stehender impfstoff gegen krebs
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
WO2018191363A8 (en) Targeted combination therapy
DK1294747T3 (da) Syntetiske fremgangsmåder for aplidine og nye antitumorale derivater, fremgangsmåder til fremstilling og anvendelse deraf
ATE489103T1 (de) Gezielte thrombose durch gewebefaktor polypeptiden
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
EA202192757A1 (ru) Способ лечения опухолей
EA200600936A1 (ru) Способы регуляции фактора некроза опухоли альфа
MX2025004473A (es) Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, metodos terapeuticos y usos de los mismos
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
MX2025001285A (es) Composiciones para la degradacion lisosomal dirigida y metodos de uso de las mismas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties